PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
190.44%
Net income growth above 1.5x VET's 30.95%. David Dodd would see a clear bottom-line advantage if it is backed by stable operations.
6.38%
Less D&A growth vs. VET's 15.10%, reducing the hit to reported earnings. David Dodd would confirm that core assets remain sufficient.
141.65%
Well above VET's 114.39% if it’s a large positive yoy. Michael Burry would see a bigger future tax burden vs. competitor’s approach.
No Data
No Data available this quarter, please select a different quarter.
-342.49%
Both reduce yoy usage, with VET at -20.21%. Martin Whitman would find an industry or cyclical factor prompting leaner operational approaches.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-342.49%
Both reduce yoy usage, with VET at -20.21%. Martin Whitman would suspect an industry or cyclical factor pulling back on these items.
4415.47%
Some yoy increase while VET is negative at -337.36%. John Neff would see competitor possibly reining in intangible charges or revaluations more effectively than we do.
13.29%
Operating cash flow growth above 1.5x VET's 7.58%. David Dodd would confirm superior cost control or stronger revenue-to-cash conversion.
20.43%
Some CapEx rise while VET is negative at -283.23%. John Neff would see competitor possibly building capacity while we hold back expansions.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
We reduce yoy sales while VET is 0.00%. Joel Greenblatt sees competitor possibly capitalizing on market peaks or forced to raise cash while we hold tight.
-57.59%
Both yoy lines negative, with VET at -41.41%. Martin Whitman suspects a cyclical or strategic rationale for cutting extra invests in the niche.
12.58%
We have mild expansions while VET is negative at -262.89%. John Neff sees competitor possibly divesting or pausing expansions more aggressively.
90.67%
Debt repayment growth of 90.67% while VET is zero at 0.00%. Bruce Berkowitz sees a mild advantage that can reduce interest costs unless expansions demand capital here.
1.06%
Lower share issuance yoy vs. VET's 9.19%, implying less dilution. David Dodd would confirm the firm still has enough capital for expansions.
35.04%
Buyback growth of 35.04% while VET is zero at 0.00%. Bruce Berkowitz sees a modest per-share advantage that might accumulate if the stock is below intrinsic value.